CFO Departs with Substantial Severance; CEO Assumes Principal Accounting Officer Role

summarizeSummary

Skye Bioscience announced the departure of its Chief Financial Officer, Kaitlyn Arsenault, who will receive a significant severance package, and CEO Punit Dhillon will assume the role of Principal Accounting Officer.

check_boxKey Events

• Chief Financial Officer Departs

  Kaitlyn Arsenault stepped down from her position as Chief Financial Officer, effective February 20, 2026, to pursue new professional opportunities.

• Significant Severance Package

  Ms. Arsenault will receive a cash severance payment of $450,000, an additional $45,000 for her 2026 annual bonus, up to $30,000 for legal fees, and a lump sum of $41,172.48 for COBRA premiums, totaling approximately $566,172.48.

• Advisory Role and Equity Vesting

  Ms. Arsenault will serve as an advisor for an initial six-month term, during which certain outstanding equity awards will continue to vest, with accelerated vesting upon a change in control.

• CEO Assumes Additional Role

  Punit Dhillon, the company's President and Chief Executive Officer, has been appointed as the Principal Accounting Officer, effective February 20, 2026, while retaining his current roles.

auto_awesomeAnalysis

The departure of a Chief Financial Officer is a significant event for any company, particularly for a micro-cap firm like Skye Bioscience. The severance package, totaling approximately $566,172.48, represents a substantial cash outflow relative to the company's market capitalization. While the filing states the departure was not due to disagreements, the financial impact and the CEO taking on the additional role of Principal Accounting Officer could signal resource constraints or a temporary measure, which may raise questions about the company's financial leadership stability. This follows recent positive interim data, creating mixed signals for investors.